This Article examines the controversy surrounding the use of rBST, a genetically altered growth hormone, in cows so that they produce more milk. Biotechnology holds tremendous benefits for society. However, this Article examines the inadequacy of the current regulatory scheme in addressing rBST. This Article contends that the inadequate nature of the regulatory scheme is due to the fact that lawmakers are overly concerned with the protection and development of the biotechnology industry. The law, as it stands, does not take into consideration the unknown health risks of rBST.
Recommended CitationDavid Aboulafia, Pushing RBST: How the Law and the Political Process Were Used to Sell Recombinant Bovine Somatotropin to America, 15 Pace Envtl. L. Rev. 603 (1998)
Available at: http://digitalcommons.pace.edu/pelr/vol15/iss2/9